#USA #New York #Levi Korsinsky #BYAH #Park Ha Biological

Overview

Recently, investors in Park Ha Biological Technology Co., Ltd. (NASDAQ: BYAH) were alerted by Levi & Korsinsky, LLP regarding a pending securities class action. This legal action concerns stockholders who acquired securities from December 27, 2024, to July 8, 2025, a period marred by significant financial upheaval for shareholders.

Background of the Case

The securities class action emerged following a tremendous fallout in the company's stock value, which plummeted by approximately 93% in a single trading session on July 8, 2025. This catastrophic decline wiped out over $1 billion in market capitalization, raising serious concerns over the company's management disclosures and practices.

Allegations Against Executives

The lawsuit names three critical insiders as defendants. These individuals include Xiaoqiu Zhang, the company’s founder, Chairperson, and CEO, and other executives who held key financial positions. Jonathan E. Levi, the attorney representing plaintiffs, emphasizes that these parties controlled the information shared with the public, which allegedly failed to properly disclose crucial financial risks and potential manipulative trading activities.

Details of Allegations

• - Zhang allegedly controlled more than 90% of the voting power within the firm, putting him in a position where he could dictate the company's financial narratives.
• - Xiaoyan Zhu, the CFO since 2016, and Director Li Wang, appointed in July 2023, also signed important public filings that have come under scrutiny.
• - The suit claims that these executives’ significant influence over corporate disclosures allowed misleading and inaccurate information to circulate among investors.

Legal Framework

The allegations are primarily based on the Section 20(a) Control Person Framework under the Exchange Act, as well as Section 15 of the Securities Act. This implies that the company's officers and directors are not only liable to the corporate issuer but can be held personally accountable for any misleading public communications. Lies or omissions tied to their corporate responsibility have severe ramifications for both the investors and the directors themselves.

Stakes for Investors

For shareholders, this situation presents a critical opportunity to potentially recover losses incurred during the specified period. Investors are urged to gather relevant documentation, including purchase records, as they prepare to file claims by the impending deadline of September 28, 2026. A lead plaintiff may be appointed to oversee the case, usually someone with the largest financial loss, thus highlighting the importance of understanding one's status in this legal battle.

Next Steps for Affected Investors

If you are an investor who suffered losses due to the steep decline in BYAH's stock, there are several proactive steps you can undertake:
1. Document Your Losses: Collect all relevant brokerage statements that reflect your purchase dates and amounts of shares held during the class action period.
2. Contact Legal Experts: Consulting with firms like Levi & Korsinsky can provide insights into your eligibility for joining the lawsuit.
3. Monitor Deadlines: Stay informed about the forthcoming deadlines to ensure you do not miss your chance for filing a claim.
4. Stay Engaged: Regularly check for updates on the case and the implications for your investments.

Conclusion

The securities class action against Park Ha Biological Technology can have significant implications for affected investors. The unfolding legal proceedings will not only assess the financial damages but also hold key executives accountable for their roles in the company's misleading disclosures. For investors impacted by this event, engaging with legal representation to navigate this class action could pave the way for financial restitution and greater corporate governance moving forward.